For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 6,266 | |||
| General and administrative expenses | 1,555 | |||
| Total operating expenses | 7,821 | |||
| Operating loss | -7,821 | |||
| Other expense direct listing offering costs | 1,164 | |||
| Net loss and comprehensive loss | -8,985 | |||
| Basic EPS | -0.2 | |||
| Diluted EPS | -0.2 | |||
| Basic Average Shares | 45,422,581 | |||
| Diluted Average Shares | 45,422,581 | |||
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)